论文部分内容阅读
目的 了解胸腺因子D治疗慢性乙型肝炎远期疗效 ,有无延迟效应。方法 742例慢性乙型肝炎患者分成 2组进行治疗 ,治疗组 5 72例 ,接受小剂量或大剂量胸腺因子D治疗 3个月 ,小剂量为 10mg ,肌注 ,每日或隔日一次 ,大剂量为5 0mg ,静滴 ,每日或隔日一次。对照组 170例 ,接受综合治疗。治疗前两组临床生化特征具有可比性。治疗结束后随访0 .5～ 5年。以病毒复制标志HBeAg转阴为应答 ,分别于治疗结束和随访结束时判断疗效。 结果 治疗结束时治疗组应答率 2 7.73 % ,对照组 9.86% (P <0 .0 0 5 ) ;随访结束时治疗组应答率 43 .0 2 % ,对照组 13 .90 % (P <0 .0 0 5 )。结论 胸腺因子D治疗慢性乙型肝炎有延迟效应
Objective To understand the long-term efficacy of thymus D in the treatment of chronic hepatitis B, with or without delayed effect. Methods A total of 742 patients with chronic hepatitis B were divided into two groups. The treatment group included 5 72 cases treated with low dose or high dose of thymus D for 3 months, and the low dose 10 mg administered intramuscularly once daily or every other day. For 50mg, intravenous infusion, daily or every other day. Control group of 170 cases, receiving comprehensive treatment. Clinical biochemical characteristics of the two groups before treatment are comparable. Follow-up after treatment 0.5 to 5 years. In response to HBeAg negative sign of viral replication, respectively, at the end of treatment and follow-up to determine the efficacy. Results The response rate of the treatment group was 7.77% at the end of treatment, 9.86% in the control group (P0.05). The response rate of the treatment group was 43.0% at the end of the follow-up period and 13.90% in the control group (P0.01). 0 0 5). Conclusion Thymic factor D has a delayed effect on chronic hepatitis B